首页 > 最新文献

Expert Review of Medical Devices最新文献

英文 中文
Single-lead VDD pacing: a literature review on short-term and long-term performance. 单导联VDD起搏:短期和长期性能的文献综述。
IF 3.1 3区 医学 Q3 ENGINEERING, BIOMEDICAL Pub Date : 2023-03-01 DOI: 10.1080/17434440.2023.2178901
Davide Antonio Mei, Jacopo Francesco Imberti, Marco Vitolo, Niccolò Bonini, Luigi Gerra, Giulio Francesco Romiti, Marco Proietti, Gregory Y H Lip, Giuseppe Boriani

Introduction: VDD pacing system was introduced more than 30 years ago. Its use is considered by the 2021 European Society of Cardiology guidelines on cardiac pacing as a potential alternative to dual chambers system for patients with atrioventricular block and normal sinus node function.

Areas covered: In this article, we performed a narrative review of current literature in order to identify the strengths and weaknesses of this pacing system. VDD system allows the maintenance of AV synchronous pacing and its hemodynamic advantages. Some disadvantages may be related to the non-negligible incidence of atrial undersensing and the possible subsequent need for upgrade to DDD system. On the other hand, shorter implantation time and lower complications rate may be advantages.

Expert opinion: In the modern pacing era, VDD pacing system struggles to find its own space. However, it may still be considered as a valuable alternative to a dual-chamber pacemaker for selected patients, in specific clinical scenarios.

简介:VDD起搏系统是30多年前推出的。2021年欧洲心脏病学会心脏起搏指南认为,对于房室传导阻滞和窦房结功能正常的患者,它是双室系统的潜在替代方案。涉及领域:在本文中,我们对当前文献进行了叙述性回顾,以确定该节奏系统的优点和缺点。VDD系统可维持房室同步起搏及其血流动力学优势。一些缺点可能与不可忽视的心房感应不足发生率和可能随后需要升级到DDD系统有关。另一方面,较短的植入时间和较低的并发症发生率可能是优势。专家意见:在现代起搏时代,VDD起搏系统努力寻找自己的空间。然而,在特定的临床情况下,它可能仍然被认为是有价值的替代双室起搏器的选择。
{"title":"Single-lead VDD pacing: a literature review on short-term and long-term performance.","authors":"Davide Antonio Mei,&nbsp;Jacopo Francesco Imberti,&nbsp;Marco Vitolo,&nbsp;Niccolò Bonini,&nbsp;Luigi Gerra,&nbsp;Giulio Francesco Romiti,&nbsp;Marco Proietti,&nbsp;Gregory Y H Lip,&nbsp;Giuseppe Boriani","doi":"10.1080/17434440.2023.2178901","DOIUrl":"https://doi.org/10.1080/17434440.2023.2178901","url":null,"abstract":"<p><strong>Introduction: </strong>VDD pacing system was introduced more than 30 years ago. Its use is considered by the 2021 European Society of Cardiology guidelines on cardiac pacing as a potential alternative to dual chambers system for patients with atrioventricular block and normal sinus node function.</p><p><strong>Areas covered: </strong>In this article, we performed a narrative review of current literature in order to identify the strengths and weaknesses of this pacing system. VDD system allows the maintenance of AV synchronous pacing and its hemodynamic advantages. Some disadvantages may be related to the non-negligible incidence of atrial undersensing and the possible subsequent need for upgrade to DDD system. On the other hand, shorter implantation time and lower complications rate may be advantages.</p><p><strong>Expert opinion: </strong>In the modern pacing era, VDD pacing system struggles to find its own space. However, it may still be considered as a valuable alternative to a dual-chamber pacemaker for selected patients, in specific clinical scenarios.</p>","PeriodicalId":12330,"journal":{"name":"Expert Review of Medical Devices","volume":"20 3","pages":"187-197"},"PeriodicalIF":3.1,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9488937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Development of theranostic wound dressings: harnessing the knowledge of biospecific interactions at the biomaterial interface to promote healing and identify biomarkers. 治疗性伤口敷料的发展:利用生物材料界面上生物特异性相互作用的知识来促进愈合和识别生物标志物。
IF 3.1 3区 医学 Q3 ENGINEERING, BIOMEDICAL Pub Date : 2023-03-01 DOI: 10.1080/17434440.2023.2181694
Shirin Saberianpour, Gianluca Melotto, Rachel Forss, Lucy Redhead, Jacqueline Elsom, Nadia Terrazini, Susan Sandeman, Dipak Sarker, Giselda Bucca, Andrew Hesketh, Cyril Crua, Matteo Santin
Chronic wounds are widely recognized as a global health challenge, but both our understanding of wound biology and the implementation of technological innovations for their treatment have made only limited progress in the last few decades [1]. Currently, the clinical assessment of the wound is based on the experience of the clinicians who follow recommendations taken from a range of available guidelines and choose commercially available wound dressings on the basis of their suitability to the wound conditions [2]. For example, the Wounds UK’s best practice statement on the management of chronic wounds recommends several criteria for the assessment of lesions that are mainly based on a subjective clinical inspection of the overall wound bed and peri-wound area status (e.g. inflammation), the exudate volume and viscosity, pain, and infectiongenerated malodor. Methods of wound size measurement provide quantitative data, but they suffer from limited intra-rater reliability. Likewise, the choice of the most suitable wound dressing is made with the aim of providing biological conditions favorable to healing. Despite the wide range available, wound dressings are all designed with two main characteristics: (i) an absorbent layer made of a polymeric porous hydrogel capable of absorbing excess exudate while keeping the wound moist and (ii) a film (e.g. silicon) protecting the wound from external contaminants and bacteria [3]. More advanced wound dressings include anti-microbial agents (e.g. silver nanoparticles) or growth factors known to promote healing [3]. The use of the latter is limited by their costs, need for refrigerated storage conditions, and debated healing properties. In this context, up to 42% of wounds do not heal within 6 months from the first presentation, often leading to severe complications [4]. Based on these premises, the quest for both healing-promoting wound dressings and objective parameters of wound evaluation is legitimately advocated. 2. Theranostic wound dressings
{"title":"Development of theranostic wound dressings: harnessing the knowledge of biospecific interactions at the biomaterial interface to promote healing and identify biomarkers.","authors":"Shirin Saberianpour,&nbsp;Gianluca Melotto,&nbsp;Rachel Forss,&nbsp;Lucy Redhead,&nbsp;Jacqueline Elsom,&nbsp;Nadia Terrazini,&nbsp;Susan Sandeman,&nbsp;Dipak Sarker,&nbsp;Giselda Bucca,&nbsp;Andrew Hesketh,&nbsp;Cyril Crua,&nbsp;Matteo Santin","doi":"10.1080/17434440.2023.2181694","DOIUrl":"https://doi.org/10.1080/17434440.2023.2181694","url":null,"abstract":"Chronic wounds are widely recognized as a global health challenge, but both our understanding of wound biology and the implementation of technological innovations for their treatment have made only limited progress in the last few decades [1]. Currently, the clinical assessment of the wound is based on the experience of the clinicians who follow recommendations taken from a range of available guidelines and choose commercially available wound dressings on the basis of their suitability to the wound conditions [2]. For example, the Wounds UK’s best practice statement on the management of chronic wounds recommends several criteria for the assessment of lesions that are mainly based on a subjective clinical inspection of the overall wound bed and peri-wound area status (e.g. inflammation), the exudate volume and viscosity, pain, and infectiongenerated malodor. Methods of wound size measurement provide quantitative data, but they suffer from limited intra-rater reliability. Likewise, the choice of the most suitable wound dressing is made with the aim of providing biological conditions favorable to healing. Despite the wide range available, wound dressings are all designed with two main characteristics: (i) an absorbent layer made of a polymeric porous hydrogel capable of absorbing excess exudate while keeping the wound moist and (ii) a film (e.g. silicon) protecting the wound from external contaminants and bacteria [3]. More advanced wound dressings include anti-microbial agents (e.g. silver nanoparticles) or growth factors known to promote healing [3]. The use of the latter is limited by their costs, need for refrigerated storage conditions, and debated healing properties. In this context, up to 42% of wounds do not heal within 6 months from the first presentation, often leading to severe complications [4]. Based on these premises, the quest for both healing-promoting wound dressings and objective parameters of wound evaluation is legitimately advocated. 2. Theranostic wound dressings","PeriodicalId":12330,"journal":{"name":"Expert Review of Medical Devices","volume":"20 3","pages":"163-165"},"PeriodicalIF":3.1,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9495563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Peregrine system infusion catheter for neurolytic renal denervation in hypertension: an overview of its safety and efficacy. 游隼系统输注导管用于高血压神经溶解性肾去神经:其安全性和有效性综述。
IF 3.1 3区 医学 Q3 ENGINEERING, BIOMEDICAL Pub Date : 2023-03-01 DOI: 10.1080/17434440.2023.2183838
Adam Janas, Wojciech Wojakowski

Introduction: Resistant hypertension (HTN), despite the tremendous advances in pharmacotherapy, is a major global problem. Transcatheter renal denervation (RDN) could be a pertinent strategy for resistant HTN and patients with poor pharmacotherapy adherence. Nonetheless, the adoption of energy-based RDN in clinical practice is slow and alternative approaches are needed.

Areas covered: The review focuses on the assessment of the Peregrine System Infusion Catheters. The system is designed for chemically mediated transcatheter RDN by the infusion publications on the Peregrine system. The theoretical assumptions for chemically mediated RDN, design of the system, data from preclinical and clinical studies, and further perspectives are discussed.

Expert opinion: Peregrine System Infusion Catheters are the only catheter on the market designed for chemically mediated RDN by the infusion of the neurolytic agent. Chemical neurolysis more efficiently destroys nerves around the renal artery in comparison to energy-based catheters, due to deeper tissue penetration and circumferential distribution resulting in a wider range of effective nerve injury. Chemically mediated RDN by the infusion of the neurolytic agent (alcohol) has an excellent safety profile as confirmed in initial clinical trials which also suggested high efficacy. Currently, there is an ongoing phase III sham-control study. Other possible applications of this technology include clinical settings like heart failure or atrial fibrillation.

导言:尽管药物治疗取得了巨大进步,但顽固性高血压(HTN)仍是一个重大的全球性问题。经导管肾去神经(RDN)可能是耐药HTN和药物治疗依从性差的患者的相关策略。然而,在临床实践中采用基于能量的RDN是缓慢的,需要替代方法。涉及领域:综述的重点是对游隼系统输液管的评估。该系统是通过Peregrine系统上的输液出版物设计的化学介导的经导管RDN。讨论了化学介导RDN的理论假设、系统设计、临床前和临床研究的数据以及进一步的观点。专家意见:Peregrine系统输注导管是市场上唯一设计用于通过输注神经溶解剂化学介导的RDN的导管。与能量导尿管相比,化学神经松解术能更有效地破坏肾动脉周围的神经,这是因为化学神经松解术能穿透更深的组织,并能形成更大范围的有效神经损伤。通过输注神经溶解剂(酒精)化学介导的RDN具有极好的安全性,初步临床试验证实了这一点,这也表明了很高的疗效。目前,有一项正在进行的III期假对照研究。这项技术的其他可能应用包括临床设置,如心力衰竭或心房颤动。
{"title":"Peregrine system infusion catheter for neurolytic renal denervation in hypertension: an overview of its safety and efficacy.","authors":"Adam Janas,&nbsp;Wojciech Wojakowski","doi":"10.1080/17434440.2023.2183838","DOIUrl":"https://doi.org/10.1080/17434440.2023.2183838","url":null,"abstract":"<p><strong>Introduction: </strong>Resistant hypertension (HTN), despite the tremendous advances in pharmacotherapy, is a major global problem. Transcatheter renal denervation (RDN) could be a pertinent strategy for resistant HTN and patients with poor pharmacotherapy adherence. Nonetheless, the adoption of energy-based RDN in clinical practice is slow and alternative approaches are needed.</p><p><strong>Areas covered: </strong>The review focuses on the assessment of the Peregrine System Infusion Catheters. The system is designed for chemically mediated transcatheter RDN by the infusion publications on the Peregrine system. The theoretical assumptions for chemically mediated RDN, design of the system, data from preclinical and clinical studies, and further perspectives are discussed.</p><p><strong>Expert opinion: </strong>Peregrine System Infusion Catheters are the only catheter on the market designed for chemically mediated RDN by the infusion of the neurolytic agent. Chemical neurolysis more efficiently destroys nerves around the renal artery in comparison to energy-based catheters, due to deeper tissue penetration and circumferential distribution resulting in a wider range of effective nerve injury. Chemically mediated RDN by the infusion of the neurolytic agent (alcohol) has an excellent safety profile as confirmed in initial clinical trials which also suggested high efficacy. Currently, there is an ongoing phase III sham-control study. Other possible applications of this technology include clinical settings like heart failure or atrial fibrillation.</p>","PeriodicalId":12330,"journal":{"name":"Expert Review of Medical Devices","volume":"20 3","pages":"179-186"},"PeriodicalIF":3.1,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9119971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of patients with bicuspid and tricuspid aortic valve in transcatheter aortic valve implantation. 经导管主动脉瓣植入术中二尖瓣与三尖瓣的比较。
IF 3.1 3区 医学 Q3 ENGINEERING, BIOMEDICAL Pub Date : 2023-03-01 DOI: 10.1080/17434440.2023.2184686
Zhongkai Zhu, Tianyuan Xiong, Mao Chen

Background: Transcatheter aortic valve implantation (TAVI) has emerged as a safe and effective alternative to surgery for aortic stenosis (AS). However, there are still differences in the procedural process and outcome of bicuspid aortic valve (BAV) treated with TAVI compared with tricuspid aortic valve.

Areas covered: This review paper aims to summarize the main characteristics and clinical evidence of TAVI in patients with bicuspid and tricuspid aortic valves and compare the outcomes of TAVI procedure.

Expert opinion: The use of TAVI in patients with BAV has shown similar clinical outcomes compared with tricuspid aortic valve. The efficacy of TAVI for challenging BAV anatomies remains a concern due to the lack of randomized trials. Detailed preprocedural planning is of great importance in low-surgical-risk BAV patients. A better understanding of which subtypes of BAV anatomy are at greater risk for adverse outcomes can potentially benefit the selection of TAVI or open-heart surgery in low surgical risk AS patients.

背景:经导管主动脉瓣植入术(TAVI)已成为治疗主动脉瓣狭窄(as)安全有效的替代方法。然而,与三尖瓣主动脉瓣相比,TAVI治疗双尖瓣主动脉瓣(BAV)的手术过程和结果仍存在差异。涵盖领域:本文旨在总结二尖瓣和三尖瓣主动脉瓣患者TAVI的主要特征和临床证据,并比较TAVI手术的结果。专家意见:与三尖瓣主动脉瓣相比,在BAV患者中使用TAVI显示出相似的临床结果。由于缺乏随机试验,TAVI治疗BAV解剖的有效性仍然值得关注。详细的术前计划对低手术风险的BAV患者非常重要。更好地了解哪些BAV亚型有更大的不良后果风险,可能有利于低手术风险AS患者选择TAVI或心内直视手术。
{"title":"Comparison of patients with bicuspid and tricuspid aortic valve in transcatheter aortic valve implantation.","authors":"Zhongkai Zhu,&nbsp;Tianyuan Xiong,&nbsp;Mao Chen","doi":"10.1080/17434440.2023.2184686","DOIUrl":"https://doi.org/10.1080/17434440.2023.2184686","url":null,"abstract":"<p><strong>Background: </strong>Transcatheter aortic valve implantation (TAVI) has emerged as a safe and effective alternative to surgery for aortic stenosis (AS). However, there are still differences in the procedural process and outcome of bicuspid aortic valve (BAV) treated with TAVI compared with tricuspid aortic valve.</p><p><strong>Areas covered: </strong>This review paper aims to summarize the main characteristics and clinical evidence of TAVI in patients with bicuspid and tricuspid aortic valves and compare the outcomes of TAVI procedure.</p><p><strong>Expert opinion: </strong>The use of TAVI in patients with BAV has shown similar clinical outcomes compared with tricuspid aortic valve. The efficacy of TAVI for challenging BAV anatomies remains a concern due to the lack of randomized trials. Detailed preprocedural planning is of great importance in low-surgical-risk BAV patients. A better understanding of which subtypes of BAV anatomy are at greater risk for adverse outcomes can potentially benefit the selection of TAVI or open-heart surgery in low surgical risk AS patients.</p>","PeriodicalId":12330,"journal":{"name":"Expert Review of Medical Devices","volume":"20 3","pages":"209-220"},"PeriodicalIF":3.1,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9119477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tests for the identification of reflex syncope mechanism. 鉴别反射性晕厥机制的试验。
IF 3.1 3区 医学 Q3 ENGINEERING, BIOMEDICAL Pub Date : 2023-02-01 DOI: 10.1080/17434440.2023.2174428
Michele Brignole, Giulia Rivasi, Artur Fedorowski, Marcus Ståhlberg, Antonella Groppelli, Andrea Ungar

Introduction: Treatment efficacy of reflex syncope is mainly related to the mechanism underlying syncope rather than its etiology or clinical presentation. The predominant mechanism underlying reflex syncope can be assigned to hypotensive or to bradycardic phenotypes.

Areas covered: Methodology and diagnostic criteria of the most useful tests for the identification of hypotensive and bradycardic phenotypes are discussed. Diagnostic tests for the hypotensive phenotype include office blood pressure measurement with active standing test, home, and wearable blood pressure monitoring, 24-h ambulatory blood pressure monitoring and tilt table test. Diagnostic tests for the bradycardic phenotype include carotid sinus massage, tilt table test and prolonged ECG monitoring.

Expert opinion: In reflex syncope, the documentation of bradycardia/asystole during a syncopal episode does not rule out the possibility that a preceding or parallel hypotensive reflex plays an important role. Similarly, even when a hypotensive mechanism is established, the possibility of an associated cardioinhibitory reflex should be investigated. Investigating the mechanism of reflex syncope is mandatory in patients with severe recurrent episodes, with the final aim to develop a personalized treatment strategy. Recent trials have demonstrated the benefits of personalized mechanism-based therapy, thus highlighting the importance of a comprehensive assessment of the mechanisms underlying syncope.

导语:反射性晕厥的治疗效果主要与晕厥的发病机制有关,而与病因或临床表现无关。反射性晕厥的主要机制可归因于低血压或心动过缓表型。涵盖的领域:方法和诊断标准的最有用的测试,以确定低血压和心动过缓表型进行了讨论。低血压表型的诊断试验包括办公室血压测量和主动站立试验,家庭和可穿戴血压监测,24小时动态血压监测和倾斜台试验。心动过缓表型的诊断试验包括颈动脉窦按摩、倾斜试验和长时间心电图监测。专家意见:在反射性晕厥中,晕厥发作时的心动过缓/心跳停止的记录不能排除先前或平行的低血压反射起重要作用的可能性。同样,即使确立了降压机制,也应调查相关的心脏抑制反射的可能性。研究反射性晕厥的发生机制对于严重复发性晕厥的患者是必要的,最终目的是制定个性化的治疗策略。最近的试验已经证明了个性化的基于机制的治疗的益处,因此强调了全面评估晕厥机制的重要性。
{"title":"Tests for the identification of reflex syncope mechanism.","authors":"Michele Brignole,&nbsp;Giulia Rivasi,&nbsp;Artur Fedorowski,&nbsp;Marcus Ståhlberg,&nbsp;Antonella Groppelli,&nbsp;Andrea Ungar","doi":"10.1080/17434440.2023.2174428","DOIUrl":"https://doi.org/10.1080/17434440.2023.2174428","url":null,"abstract":"<p><strong>Introduction: </strong>Treatment efficacy of reflex syncope is mainly related to the mechanism underlying syncope rather than its etiology or clinical presentation. The predominant mechanism underlying reflex syncope can be assigned to hypotensive or to bradycardic phenotypes.</p><p><strong>Areas covered: </strong>Methodology and diagnostic criteria of the most useful tests for the identification of hypotensive and bradycardic phenotypes are discussed. Diagnostic tests for the hypotensive phenotype include office blood pressure measurement with active standing test, home, and wearable blood pressure monitoring, 24-h ambulatory blood pressure monitoring and tilt table test. Diagnostic tests for the bradycardic phenotype include carotid sinus massage, tilt table test and prolonged ECG monitoring.</p><p><strong>Expert opinion: </strong>In reflex syncope, the documentation of bradycardia/asystole during a syncopal episode does not rule out the possibility that a preceding or parallel hypotensive reflex plays an important role. Similarly, even when a hypotensive mechanism is established, the possibility of an associated cardioinhibitory reflex should be investigated. Investigating the mechanism of reflex syncope is mandatory in patients with severe recurrent episodes, with the final aim to develop a personalized treatment strategy. Recent trials have demonstrated the benefits of personalized mechanism-based therapy, thus highlighting the importance of a comprehensive assessment of the mechanisms underlying syncope.</p>","PeriodicalId":12330,"journal":{"name":"Expert Review of Medical Devices","volume":"20 2","pages":"109-119"},"PeriodicalIF":3.1,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9072634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Partial vs full glottic view with CMACTM D blade intubation of airway with simulated cervical spine injury: a randomized controlled trial. CMACTM - D叶片气管插管对模拟颈椎损伤的部分声门观察与全声门观察:一项随机对照试验。
IF 3.1 3区 医学 Q3 ENGINEERING, BIOMEDICAL Pub Date : 2023-02-01 DOI: 10.1080/17434440.2023.2174850
Chao Chia Cheong, Soon Yiu Ong, Siu Min Lim, Wan Zakaria Wan A, Marzida Mansor, Sook Hui Chaw

Purpose: A previous study reported a shorter time to tracheal intubation by reducing percentage of glottic opening (POGO) view to <50% when intubating a normal adult airway using the GlidescopeTM blade. We evaluate the efficacy of reducing POGO to <50% when intubating patients with rigid cervical immobilization using CMACTM D blade.

Methods: One hundred and four adult patients were randomized to group POGO 100% or POGO <50% . Laryngoscopy was performed by advancing tip of the D blade at vallecula. POGO 100% was achieved by exerting upward force to displace epiglottis until glottic opening from the anterior commissure to inter arytenoid notch. POGO < 50% was acquired by withdrawing the D blade tip dorsally from vallecula. The primary outcome was time to intubation.

Results: The median time (IQR) to successful intubation was 29 (25-35) seconds for group POGO < 50% and 34 (28-40) seconds for group with POGO 100% (difference in medians, 5 seconds; 95% confidence interval, 2 to 8, p = 0.003). Complications were minor.

Conclusion: Using the CMACTM D blade with a reduced POGO in patients with cervical spine immobilization resulted in faster tracheal intubation.

Trial registration: The trial is registered at ClinicalTrial.gov (CT.gov identifier: NCT04833166).

目的:先前的一项研究报道了通过减少声门开口(POGO)视野到TM刀片的百分比来缩短气管插管时间。我们评估了将POGO还原为TM D刀片的疗效。结果:POGO < 50%组插管成功的中位时间(IQR)为29(25-35)秒,POGO 100%组插管成功的中位时间(IQR)为34(28-40)秒(中位差异为5秒;95%置信区间,2 ~ 8,p = 0.003)。并发症很少。结论:颈椎固定患者使用CMACTM - D刀片降低POGO可加快气管插管速度。试验注册:该试验在ClinicalTrial.gov (CT.gov标识符:NCT04833166)上注册。
{"title":"Partial vs full glottic view with CMAC<sup>TM</sup> D blade intubation of airway with simulated cervical spine injury: a randomized controlled trial.","authors":"Chao Chia Cheong,&nbsp;Soon Yiu Ong,&nbsp;Siu Min Lim,&nbsp;Wan Zakaria Wan A,&nbsp;Marzida Mansor,&nbsp;Sook Hui Chaw","doi":"10.1080/17434440.2023.2174850","DOIUrl":"https://doi.org/10.1080/17434440.2023.2174850","url":null,"abstract":"<p><strong>Purpose: </strong>A previous study reported a shorter time to tracheal intubation by reducing percentage of glottic opening (POGO) view to <50% when intubating a normal adult airway using the Glidescope<sup>TM</sup> blade. We evaluate the efficacy of reducing POGO to <50% when intubating patients with rigid cervical immobilization using CMAC<sup>TM</sup> D blade.</p><p><strong>Methods: </strong>One hundred and four adult patients were randomized to group POGO 100% or POGO <50% . Laryngoscopy was performed by advancing tip of the D blade at vallecula. POGO 100% was achieved by exerting upward force to displace epiglottis until glottic opening from the anterior commissure to inter arytenoid notch. POGO < 50% was acquired by withdrawing the D blade tip dorsally from vallecula. The primary outcome was time to intubation.</p><p><strong>Results: </strong>The median time (IQR) to successful intubation was 29 (25-35) seconds for group POGO < 50% and 34 (28-40) seconds for group with POGO 100% (difference in medians, 5 seconds; 95% confidence interval, 2 to 8, p = 0.003). Complications were minor.</p><p><strong>Conclusion: </strong>Using the CMAC<sup>TM</sup> D blade with a reduced POGO in patients with cervical spine immobilization resulted in faster tracheal intubation.</p><p><strong>Trial registration: </strong>The trial is registered at ClinicalTrial.gov (CT.gov identifier: NCT04833166).</p>","PeriodicalId":12330,"journal":{"name":"Expert Review of Medical Devices","volume":"20 2","pages":"151-160"},"PeriodicalIF":3.1,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9383243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Addendum. 附录。
IF 3.1 3区 医学 Q3 ENGINEERING, BIOMEDICAL Pub Date : 2023-02-01 DOI: 10.1080/17434440.2022.2152229
Jack Kingdon, Adam Gwozdz, Rachael Morris, Stephen Black, Alberto Smith, Prakash Saha
{"title":"Addendum.","authors":"Jack Kingdon,&nbsp;Adam Gwozdz,&nbsp;Rachael Morris,&nbsp;Stephen Black,&nbsp;Alberto Smith,&nbsp;Prakash Saha","doi":"10.1080/17434440.2022.2152229","DOIUrl":"https://doi.org/10.1080/17434440.2022.2152229","url":null,"abstract":"","PeriodicalId":12330,"journal":{"name":"Expert Review of Medical Devices","volume":"20 2","pages":"161"},"PeriodicalIF":3.1,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9495034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
EVO/EVO+ Visian Implantable Collamer Lenses for the correction of myopia and myopia with astigmatism. EVO/EVO+ Visian植入式屈光体镜片用于矫正近视及近视伴散光。
IF 3.1 3区 医学 Q3 ENGINEERING, BIOMEDICAL Pub Date : 2023-02-01 DOI: 10.1080/17434440.2023.2174429
Elena Martínez-Plaza, Alberto López-de la Rosa, Alberto López-Miguel, Alfredo Holgueras, Miguel J Maldonado

Introduction: Intraocular lens implantation in phakic eyes for the correction of refractive error is currently a widespread procedure. The EVO and EVO+ Visian Implantable Collamer Lenses (ICL) are two of the most prevalent lenses implanted. They incorporate a central orifice to avoid the need for iridotomy. The main difference between both ICL is the higher optical diameter zone provided by the EVO+, allowing a better quality of vision at night. This review aims to provide an overview of the current ICL models available for correcting myopia and myopic astigmatism.

Areas covered: During the last decade, more than 100 scientific papers analyzing the performance of EVO and EVO+ lenses have been published. This review describes the objective visual performance achieved with the implantation of central hole ICL lenses and the subjective perception of the patients implanted with these lenses. In addition, the safety and the potential complications associated with undergoing an EVO and EVO+ ICL implantation have been addressed.

Expert opinion: Refractive surgeons and candidates to undergo ICL implantation should be aware of the excellent safety and visual outcomes provided by the implantation of central hole ICL lenses. However, future research could address minor issues currently not resolved.

导读:人工晶状体植入术是目前广泛应用的一种治疗屈光不正的方法。EVO和EVO+ Visian植入式Collamer lens (ICL)是目前最流行的两种植入式晶体。它们包括一个中心孔,以避免虹膜切开术的需要。两种ICL的主要区别是EVO+提供了更高的光学直径区域,允许夜间更好的视觉质量。本文综述了目前用于矫正近视和近视散光的ICL模型。研究领域:在过去的十年中,已经发表了100多篇分析EVO和EVO+镜头性能的科学论文。本文综述了中心孔人工晶体植入术后的客观视觉表现以及植入术患者的主观感觉。此外,还讨论了EVO和EVO+ ICL植入的安全性和潜在并发症。专家意见:屈光外科医生和接受ICL植入的候选人应该意识到中心孔ICL晶状体植入所提供的极好的安全性和视力效果。然而,未来的研究可以解决目前尚未解决的小问题。
{"title":"EVO/EVO+ Visian Implantable Collamer Lenses for the correction of myopia and myopia with astigmatism.","authors":"Elena Martínez-Plaza,&nbsp;Alberto López-de la Rosa,&nbsp;Alberto López-Miguel,&nbsp;Alfredo Holgueras,&nbsp;Miguel J Maldonado","doi":"10.1080/17434440.2023.2174429","DOIUrl":"https://doi.org/10.1080/17434440.2023.2174429","url":null,"abstract":"<p><strong>Introduction: </strong>Intraocular lens implantation in phakic eyes for the correction of refractive error is currently a widespread procedure. The EVO and EVO+ Visian Implantable Collamer Lenses (ICL) are two of the most prevalent lenses implanted. They incorporate a central orifice to avoid the need for iridotomy. The main difference between both ICL is the higher optical diameter zone provided by the EVO+, allowing a better quality of vision at night. This review aims to provide an overview of the current ICL models available for correcting myopia and myopic astigmatism.</p><p><strong>Areas covered: </strong>During the last decade, more than 100 scientific papers analyzing the performance of EVO and EVO+ lenses have been published. This review describes the objective visual performance achieved with the implantation of central hole ICL lenses and the subjective perception of the patients implanted with these lenses. In addition, the safety and the potential complications associated with undergoing an EVO and EVO+ ICL implantation have been addressed.</p><p><strong>Expert opinion: </strong>Refractive surgeons and candidates to undergo ICL implantation should be aware of the excellent safety and visual outcomes provided by the implantation of central hole ICL lenses. However, future research could address minor issues currently not resolved.</p>","PeriodicalId":12330,"journal":{"name":"Expert Review of Medical Devices","volume":"20 2","pages":"75-83"},"PeriodicalIF":3.1,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10827622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Transcatheter edge-to-edge mitral valve repair in mitral regurgitation: current status and future prospects. 经导管二尖瓣边缘到边缘修复二尖瓣反流:现状及未来展望。
IF 3.1 3区 医学 Q3 ENGINEERING, BIOMEDICAL Pub Date : 2023-02-01 DOI: 10.1080/17434440.2022.2098013
Lukas Stolz, Daniel Braun, Satoshi Higuchi, Martin Orban, Philipp M Doldi, Thomas J Stocker, Ludwig T Weckbach, Mirjam G Wild, Christian Hagl, Steffen Massberg, Michael Näbauer, Jörg Hausleiter, Mathias Orban
ABSTRACT Introduction Mitral regurgitation (MR) is associated with substantial morbidity and mortality. Within the past 15 years, mitral valve edge-to-edge repair (M-TEER) has developed from an experimental approach to a guideline-recommended, safe, and effective treatment option for patients with severe primary or secondary mitral regurgitation. Areas covered This review covered relevant publications of M-TEER and summarizes the development of M-TEER devices within the last 15 years. It outlines anatomical challenges which drove the evolution of M-TEER devices, provides an overview about the current state of clinical application and research, and offers an outlook into the future of transcatheter mitral valve treatment. Expert opinion The development and refinement of new M-TEER device generations offer the possibility to treat a wide range of mitral valve anatomies. Choosing the best device for the individual anatomic properties of the patients and considering comorbidities is the key to maximized MR reduction, minimalized complication rates, and thus optimized postinterventional prognosis. Independent from prognostic implications, quality of life has become an important patient-centered outcome that can be improved by M-TEER in virtually all patients treated.
二尖瓣反流(MR)与大量的发病率和死亡率相关。在过去的15年里,二尖瓣边缘到边缘修复(M-TEER)已经从一种实验方法发展成为一种指南推荐的、安全有效的治疗方案,用于严重的原发性或继发性二尖瓣反流患者。涵盖领域:本综述涵盖了M-TEER的相关出版物,并总结了近15年来M-TEER设备的发展。它概述了驱动M-TEER装置发展的解剖学挑战,概述了目前的临床应用和研究状况,并展望了经导管二尖瓣治疗的未来。专家意见:新一代M-TEER装置的发展和改进为治疗广泛的二尖瓣解剖提供了可能性。根据患者的个体解剖特性选择最佳的器械并考虑合并症是最大限度地降低MR,减少并发症发生率,从而优化介入后预后的关键。与预后无关,生活质量已成为一个重要的以患者为中心的结果,几乎所有接受M-TEER治疗的患者都可以通过M-TEER改善生活质量。
{"title":"Transcatheter edge-to-edge mitral valve repair in mitral regurgitation: current status and future prospects.","authors":"Lukas Stolz,&nbsp;Daniel Braun,&nbsp;Satoshi Higuchi,&nbsp;Martin Orban,&nbsp;Philipp M Doldi,&nbsp;Thomas J Stocker,&nbsp;Ludwig T Weckbach,&nbsp;Mirjam G Wild,&nbsp;Christian Hagl,&nbsp;Steffen Massberg,&nbsp;Michael Näbauer,&nbsp;Jörg Hausleiter,&nbsp;Mathias Orban","doi":"10.1080/17434440.2022.2098013","DOIUrl":"https://doi.org/10.1080/17434440.2022.2098013","url":null,"abstract":"ABSTRACT Introduction Mitral regurgitation (MR) is associated with substantial morbidity and mortality. Within the past 15 years, mitral valve edge-to-edge repair (M-TEER) has developed from an experimental approach to a guideline-recommended, safe, and effective treatment option for patients with severe primary or secondary mitral regurgitation. Areas covered This review covered relevant publications of M-TEER and summarizes the development of M-TEER devices within the last 15 years. It outlines anatomical challenges which drove the evolution of M-TEER devices, provides an overview about the current state of clinical application and research, and offers an outlook into the future of transcatheter mitral valve treatment. Expert opinion The development and refinement of new M-TEER device generations offer the possibility to treat a wide range of mitral valve anatomies. Choosing the best device for the individual anatomic properties of the patients and considering comorbidities is the key to maximized MR reduction, minimalized complication rates, and thus optimized postinterventional prognosis. Independent from prognostic implications, quality of life has become an important patient-centered outcome that can be improved by M-TEER in virtually all patients treated.","PeriodicalId":12330,"journal":{"name":"Expert Review of Medical Devices","volume":"20 2","pages":"99-108"},"PeriodicalIF":3.1,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10825587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Prevention of prosthetic joint infection/surgical site infection: what did the International Consensus Meeting decide? 预防假体关节感染/手术部位感染:国际共识会议决定了什么?
IF 3.1 3区 医学 Q3 ENGINEERING, BIOMEDICAL Pub Date : 2023-02-01 DOI: 10.1080/17434440.2023.2174849
Farideh Najafi, Neusha Hollingsworth, Nicholas V Peterson, Javad Parvizi
Surgical site infection (SSI) and periprosthetic joint infection (PJI) are devastating complications following orthopedic surgery [1]. Hence, the prevention of these infections is of paramount importance. During the 2018 International Consensus Meeting (ICM), numerous proposals regarding the prevention of SSI/PJI were discussed. A large contingent comprising 869 delegates from 68 countries and different subspecialties (hip and knee, foot and ankle, oncology, pediatrics, shoulder and elbow, spine, sports, and trauma) worked to develop consensus on the most effective methods of prevention of SSI/PJI. The conclusions and recommendations of ICM 2018 will be discussed in this article.
{"title":"Prevention of prosthetic joint infection/surgical site infection: what did the International Consensus Meeting decide?","authors":"Farideh Najafi,&nbsp;Neusha Hollingsworth,&nbsp;Nicholas V Peterson,&nbsp;Javad Parvizi","doi":"10.1080/17434440.2023.2174849","DOIUrl":"https://doi.org/10.1080/17434440.2023.2174849","url":null,"abstract":"Surgical site infection (SSI) and periprosthetic joint infection (PJI) are devastating complications following orthopedic surgery [1]. Hence, the prevention of these infections is of paramount importance. During the 2018 International Consensus Meeting (ICM), numerous proposals regarding the prevention of SSI/PJI were discussed. A large contingent comprising 869 delegates from 68 countries and different subspecialties (hip and knee, foot and ankle, oncology, pediatrics, shoulder and elbow, spine, sports, and trauma) worked to develop consensus on the most effective methods of prevention of SSI/PJI. The conclusions and recommendations of ICM 2018 will be discussed in this article.","PeriodicalId":12330,"journal":{"name":"Expert Review of Medical Devices","volume":"20 2","pages":"71-74"},"PeriodicalIF":3.1,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9495078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Expert Review of Medical Devices
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1